Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer.

Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC.

J Immunol. 2019 Jun 15;202(12):3458-3467. doi: 10.4049/jimmunol.1801022. Epub 2019 Apr 29.

PMID:
31036766
2.

Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.

Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, Papaliodis GN, Kodati S, Bishop R, Magone MT, Sobrin L, Sen HN.

Ocul Immunol Inflamm. 2019 Apr 23:1-6. doi: 10.1080/09273948.2019.1583347. [Epub ahead of print]

PMID:
31013173
3.

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.

Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N.

Clin Cancer Res. 2019 Jun 15;25(12):3689-3701. doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7.

PMID:
30846479
4.

Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival.

Amara CS, Ambati CR, Vantaku V, Badrajee Piyarathna DW, Donepudi SR, Ravi SS, Arnold JM, Putluri V, Chatta G, Guru KA, Badr H, Terris MK, Bollag RJ, Sreekumar A, Apolo AB, Putluri N.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):770-781. doi: 10.1158/1055-9965.EPI-18-0936. Epub 2019 Jan 14.

PMID:
30642841
5.

Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.

Vantaku V, Donepudi SR, Piyarathna DWB, Amara CS, Ambati CR, Tang W, Putluri V, Chandrashekar DS, Varambally S, Terris MK, Davies K, Ambs S, Bollag R, Apolo AB, Sreekumar A, Putluri N.

Cancer. 2019 Mar 15;125(6):921-932. doi: 10.1002/cncr.31890. Epub 2019 Jan 2.

PMID:
30602056
6.

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.

Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, Gulley JL, Bilusic M.

J Immunother Cancer. 2018 Dec 18;6(1):150. doi: 10.1186/s40425-018-0473-0.

7.

Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer.

Weisman AJ, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Humm JL, Apolo AB, Larson SM, Morris MJ, Perlman SB, Liu G, Jeraj R.

Prostate Cancer Prostatic Dis. 2019 May;22(2):324-330. doi: 10.1038/s41391-018-0110-5. Epub 2018 Nov 9.

PMID:
30413807
8.

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM.

Clin Genitourin Cancer. 2019 Feb;17(1):1-6. doi: 10.1016/j.clgc.2018.09.005. Epub 2018 Sep 12.

PMID:
30287223
9.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
10.

Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Nadal R, Apolo AB.

Curr Treat Options Oncol. 2018 May 28;19(7):36. doi: 10.1007/s11864-018-0551-z. Review.

PMID:
29808294
11.

Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.

Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB.

Clin Genitourin Cancer. 2018 Apr;16(2):117-129. doi: 10.1016/j.clgc.2017.11.002. Epub 2017 Dec 6. Review.

12.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

PMID:
29289519
13.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB.

Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5. Erratum in: Lancet Oncol. 2018 Jul;19(7):e335.

PMID:
29217288
14.

Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.

Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC.

J Urol. 2018 May;199(5):1129-1142. doi: 10.1016/j.juro.2017.10.041. Epub 2017 Nov 4. Review. Erratum in: J Urol. 2018 Sep;200(3):660.

PMID:
29113841
15.

Magnetic Nanoparticle Mediated Steroid Delivery Mitigates Cisplatin Induced Hearing Loss.

Ramaswamy B, Roy S, Apolo AB, Shapiro B, Depireux DA.

Front Cell Neurosci. 2017 Sep 13;11:268. doi: 10.3389/fncel.2017.00268. eCollection 2017.

16.

Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.

Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, Larson SM, Morris MJ, Liu G, Jeraj R.

J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27.

17.

Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Bagheri MH, Ahlman MA, Lindenberg L, Turkbey B, Lin J, Cahid Civelek A, Malayeri AA, Agarwal PK, Choyke PL, Folio LR, Apolo AB.

Urol Oncol. 2017 Jul;35(7):473-491. doi: 10.1016/j.urolonc.2017.04.014. Epub 2017 May 12. Review.

18.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.

J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.

19.

Immunotherapy: a new treatment paradigm in bladder cancer.

Davarpanah NN, Yuno A, Trepel JB, Apolo AB.

Curr Opin Oncol. 2017 Mar 16. doi: 10.1097/CCO.0000000000000366. [Epub ahead of print]

20.

Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials.

Machado LB, Apolo AB, Steinberg SM, Folio LR.

AJR Am J Roentgenol. 2017 Feb;208(2):W31-W37. doi: 10.2214/AJR.16.16845.

PMID:
28112557
21.

ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases.

Goyal N, Apolo AB, Berman ED, Bagheri MH, Levine JE, Glod JW, Kaplan RN, Machado LB, Folio LR.

J Digit Imaging. 2017 Jun;30(3):275-286. doi: 10.1007/s10278-016-9938-1.

22.

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Lin C, Bradshaw T, Perk T, Harmon S, Eickhoff J, Jallow N, Choyke PL, Dahut WL, Larson S, Humm JL, Perlman S, Apolo AB, Morris MJ, Liu G, Jeraj R.

J Nucl Med. 2016 Dec;57(12):1872-1879. Epub 2016 Jul 21.

23.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

24.

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.

Abida W, Milowsky MI, Ostrovnaya I, Gerst SR, Rosenberg JE, Voss MH, Apolo AB, Regazzi AM, McCoy AS, Boyd ME, Bajorin DF.

Bladder Cancer. 2016 Jan 7;2(1):111-117.

25.

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI.

World J Urol. 2017 Mar;35(3):367-378. doi: 10.1007/s00345-016-1885-4. Epub 2016 Jun 24. Review.

PMID:
27342991
26.

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.

Clin Genitourin Cancer. 2017 Feb;15(1):77-85. doi: 10.1016/j.clgc.2016.05.010. Epub 2016 May 27.

PMID:
27328856
27.

PDL1: The Illusion of an Ideal Biomarker.

Apolo AB.

Eur Urol Focus. 2016 Feb;1(3):269-271. doi: 10.1016/j.euf.2015.04.005. Epub 2015 Jun 6. No abstract available.

PMID:
28723398
28.

Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.

Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL.

J Nucl Med. 2016 Jun;57(6):886-92. doi: 10.2967/jnumed.115.166512. Epub 2016 Jan 21.

29.

The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.

Tully CM, Apolo AB, Zabor EC, Regazzi AM, Ostrovnaya I, Furberg HF, Rosenberg JE, Bajorin DF.

Cancer. 2016 Mar 1;122(5):712-21. doi: 10.1002/cncr.29801. Epub 2015 Nov 30.

30.

Immunotherapies for bladder cancer: a new hope.

Fakhrejahani F, Tomita Y, Maj-Hes A, Trepel JB, De Santis M, Apolo AB.

Curr Opin Urol. 2015 Nov;25(6):586-96. doi: 10.1097/MOU.0000000000000213. Review.

PMID:
26372038
31.

Imaging muscle-invasive and metastatic urothelial carcinoma.

Malayeri AA, Pattanayak P, Apolo AB.

Curr Opin Urol. 2015 Sep;25(5):441-8. doi: 10.1097/MOU.0000000000000208. Review.

PMID:
26222929
32.

A precision, personalized approach to the management of bladder cancer.

Apolo AB, Burger M.

Curr Opin Urol. 2015 Sep;25(5):416-7. doi: 10.1097/MOU.0000000000000195. No abstract available.

PMID:
26153639
33.

Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.

Folio LR, Turkbey EB, Steinberg SM, Apolo AB.

Eur J Radiol. 2015 Sep;84(9):1708-14. doi: 10.1016/j.ejrad.2015.05.026. Epub 2015 Jun 10.

34.

New and promising strategies in the management of bladder cancer.

Apolo AB, Vogelzang NJ, Theodorescu D.

Am Soc Clin Oncol Educ Book. 2015:105-12. doi: 10.14694/EdBook_AM.2015.35.105. Review.

35.

Trimodality therapy in bladder cancer: who, what, and when?

Premo C, Apolo AB, Agarwal PK, Citrin DE.

Urol Clin North Am. 2015 May;42(2):169-80, vii. doi: 10.1016/j.ucl.2015.02.002. Review.

36.

Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB.

Clin Genitourin Cancer. 2015 Oct;13(5):410-20. doi: 10.1016/j.clgc.2015.02.009. Epub 2015 Mar 5. Review.

37.

Emerging immunotherapies for bladder cancer.

Kim JW, Tomita Y, Trepel J, Apolo AB.

Curr Opin Oncol. 2015 May;27(3):191-200. doi: 10.1097/CCO.0000000000000177. Review.

PMID:
25811346
38.

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder.

Lee YH, Apolo AB, Agarwal PK, Bottaro DP.

Cancers (Basel). 2014 Nov 25;6(4):2313-29. doi: 10.3390/cancers6042313.

39.

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW.

JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.

PMID:
25427282
40.

A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.

41.

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.

Sternberg CN, Apolo AB.

J Clin Oncol. 2014 Dec 20;32(36):4172-3. doi: 10.1200/JCO.2014.58.5299. Epub 2014 Nov 10. No abstract available.

PMID:
25385726
42.

The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.

Fu YP, Kohaar I, Moore LE, Lenz P, Figueroa JD, Tang W, Porter-Gill P, Chatterjee N, Scott-Johnson A, Garcia-Closas M, Muchmore B, Baris D, Paquin A, Ylaya K, Schwenn M, Apolo AB, Karagas MR, Tarway M, Johnson A, Mumy A, Schned A, Guedez L, Jones MA, Kida M, Hosain GM, Malats N, Kogevinas M, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Wu X, Purdue M, Andriole GL Jr, Grubb RL 3rd, Black A, Landi MT, Caporaso NE, Vineis P, Siddiq A, Bueno-de-Mesquita HB, Trichopoulos D, Ljungberg B, Severi G, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Prescott J, Chen C, De Vivo I, Govannucci E, Hunter D, Kraft P, Lindstrom S, Gapstur SM, Jacobs EJ, Diver WR, Albanes D, Weinstein SJ, Virtamo J, Kooperberg C, Hohensee C, Rodabough RJ, Cortessis VK, Conti DV, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Haiman CA, Cussenot O, Cancel-Tassin G, Roupret M, Comperat E, Porru S, Carta A, Pavanello S, Arici C, Mastrangelo G, Grossman HB, Wang Z, Deng X, Chung CC, Hutchinson A, Burdette L, Wheeler W, Fraumeni J Jr, Chanock SJ, Hewitt SM, Silverman DT, Rothman N, Prokunina-Olsson L.

Cancer Res. 2014 Oct 15;74(20):5808-18. doi: 10.1158/0008-5472.CAN-14-1531.

43.

New facial papules in a 66-year-old woman with bladder cancer.

Nakrani RN, Ghosh A, Richard Lee CC, Agarwal PK, Apolo AB, Cowen EW.

J Am Acad Dermatol. 2014 Dec;71(6):1250-5. doi: 10.1016/j.jaad.2014.07.012. Epub 2014 Aug 7. No abstract available.

44.

Multimodal management of muscle-invasive bladder cancer.

Park JC, Citrin DE, Agarwal PK, Apolo AB.

Curr Probl Cancer. 2014 May-Jun;38(3):80-108. doi: 10.1016/j.currproblcancer.2014.06.001. Epub 2014 Jun 23. Review. No abstract available.

45.

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y.

Urol Oncol. 2015 Feb;33(2):53-64. doi: 10.1016/j.urolonc.2014.06.013. Epub 2014 Jul 25. Review.

PMID:
25065704
46.

Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.

Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD.

Oncologist. 2014 Sep;19(9):915-6. doi: 10.1634/theoncologist.2014-0153. Epub 2014 Jul 22.

47.

Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions.

Cowan NG, Chen Y, Downs TM, Bochner BH, Apolo AB, Porter MP, La Rochelle JC, Amling CL, Koppie TM.

Adv Urol. 2014;2014:746298. doi: 10.1155/2014/746298. Epub 2014 May 28.

48.

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS.

Urol Oncol. 2014 Jul;32(5):637-44. doi: 10.1016/j.urolonc.2013.12.012. Epub 2014 May 16.

49.

Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression.

Pichard DC, Hensley JR, Williams E, Apolo AB, Klion AD, DiGiovanna JJ.

J Am Acad Dermatol. 2014 Jun;70(6):1130-4. doi: 10.1016/j.jaad.2013.11.036. Review.

50.

Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.

Sternberg CN, Apolo AB.

J Clin Oncol. 2014 Jun 20;32(18):1868-70. doi: 10.1200/JCO.2014.55.4055. Epub 2014 May 12. No abstract available.

PMID:
24821880

Supplemental Content

Loading ...
Support Center